ResMed nominates new director
ResMed (ASX:RMD) has nominated US healthcare professional Carol J Burt for an open position on its board of directors.
Shareholders in the sleep-disordered breathing technology company will vote on whether to appoint Burt to the board at the company’s AGM on 14 November.
Burt is a principal of Burt-Hillard Investments, a private investment and consulting firm targeting the healthcare industry. She has previously held roles including senior vice president of corporate finance and development for health benefits company WellPoint.
ResMed CEO Mick Farrell said if appointed, Burt will play a key role in helping to guide the company’s future.
“Government and private health care payers are beginning to realise the significant benefits of proactively treating sleep-disordered breathing among their covered lives,” he said.
“Reducing costs associated with treatment of chronic conditions such as hypertension and heart failure is escalating as a priority in care management. With Ms Burt’s guidance, we’d like to accelerate that escalation.”
If appointed, Burt will be replacing Michael Quinn, a 21-year veteran of the ResMed board who will not be standing for re-election.
ResMed has separately announced that it will release its September-quarter financial results on 24 October.
ResMed (ASX:RMD) shares were trading 0.79% lower at $5.685 as of around 1 pm on Friday.
Targeting the stress system reduces Parkinson's tremors
The commonly used Parkinson's drug levodopa usually helps with tremors, but it tends to be...
DDX53 gene linked to autism spectrum disorder
While DDX53, located on the X chromosome, is known to play a role in brain development...
ADHD drug shows promise for treating meth addiction
A prescription medication used to treat attention deficit hyperactivity disorder (ADHD) could be...
